![Sina Bavari](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Sina Bavari
Corporate Officer/Principal presso TONIX PHARMACEUTICALS HOLDING CORP.
Profilo
Sina Bavari is the founder of Healion Bio, Inc. He currently works as the EVP-Infectious Disease Research & Development at Tonix Pharmaceuticals Holding Corp.
Previously, he worked as the Chief Scientific Officer at the U.S.
Army Medical Research Institute for Infectious Diseases.
Bavari holds a graduate degree from the University of Southern California and a doctorate from the University of Nebraska Medical Center.
Posizioni attive di Sina Bavari
Società | Posizione | Inizio |
---|---|---|
TONIX PHARMACEUTICALS HOLDING CORP. | Corporate Officer/Principal | 25/07/2022 |
Healion Bio, Inc.
![]() Healion Bio, Inc. BiotechnologyHealth Technology Part of Tonix Pharmaceuticals Holding Corp., Healion Bio, Inc. is a biotechnology development company based in Frederick, MD. The company is focused on developing the next generation of antiviral compounds, with two antiviral platforms: the HB-100 series of protease inhibitors and the HB-200/300 series of next-generation antiviral biologics. The HB-100 series is a first-in-class antiviral with an orthogonal mechanism of action to existing drugs. The company was founded by Sina Bavari and Simon Newman, with Simon Newman serving as CEO since incorporation. Healion Bio was acquired by Tonix Pharmaceuticals Holding Corp. on February 01, 2023 for $1.20 million. | Fondatore | - |
Precedenti posizioni note di Sina Bavari
Società | Posizione | Fine |
---|---|---|
U.S. Army Medical Research Institute for Infectious Diseases | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Sina Bavari
University of Nebraska Medical Center | Doctorate Degree |
University of Southern California | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
TONIX PHARMACEUTICALS HOLDING CORP. | Health Technology |
Aziende private | 1 |
---|---|
Healion Bio, Inc.
![]() Healion Bio, Inc. BiotechnologyHealth Technology Part of Tonix Pharmaceuticals Holding Corp., Healion Bio, Inc. is a biotechnology development company based in Frederick, MD. The company is focused on developing the next generation of antiviral compounds, with two antiviral platforms: the HB-100 series of protease inhibitors and the HB-200/300 series of next-generation antiviral biologics. The HB-100 series is a first-in-class antiviral with an orthogonal mechanism of action to existing drugs. The company was founded by Sina Bavari and Simon Newman, with Simon Newman serving as CEO since incorporation. Healion Bio was acquired by Tonix Pharmaceuticals Holding Corp. on February 01, 2023 for $1.20 million. | Health Technology |
- Borsa valori
- Insiders
- Sina Bavari